PET Changes in Alzheimer's Disease (AD)
NCT00094913 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 105
Last updated 2009-05-27
Summary
The purpose of this study is to identify the earliest predictors of memory and brain deterioration in pre-clinical Alzheimer's disease using positron emission tomography (PET) to monitor brain glucose metabolism.
Conditions
- Alzheimer Disease
Sponsors & Collaborators
-
National Institute on Aging (NIA)
lead NIH
Principal Investigators
-
Mony J. de Leon, Ed.D. · Center for Brain Health, Silberstein Institute
Eligibility
- Min Age
- 20 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2004-05-31
- Completion
- 2005-04-30
Countries
- United States
Study Locations
More Related Trials
-
Health and Aging Brain Study: Health Disparities Tau Positron Emission Tomography (PET) Scan Study
NCT05076331 ·Status: UNKNOWN
-
Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI
NCT01812213 ·Status: TERMINATED ·Phase: PHASE2
-
Detecting Early Alzheimer's Using MR
NCT05614310 ·Status: RECRUITING
-
Positron Emission Tomography of Amyloid in Alzheimer's Disease
NCT00205621 ·Status: SUSPENDED ·Phase: PHASE1
-
Orientation in AD Patients: PET-MR Study
NCT03030365 ·Status: UNKNOWN
-
Metabolic Characterization of Alzheimer's Disease and Frontotemporal Dementia by 23Na-MRI and FDG-PET
NCT07100470 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers
NCT01826110 ·Status: COMPLETED ·Phase: PHASE1
-
Early Detection of Mild Cognitive Impairment in Individual Patients
NCT00243451 ·Status: COMPLETED
-
Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging
NCT01815112 ·Status: TERMINATED ·Phase: NA
-
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
NCT03307993 ·Status: TERMINATED ·Phase: PHASE1
-
[18F]NIDF PET Imaging in Tau-related Diseases
NCT07306598 ·Status: RECRUITING
-
MRI of Alzheimer's Disease Imaging Amyloid Plaques in Persons With and Without Memory Problems
NCT00413621 ·Status: COMPLETED
-
[18F]PI-2620 Phase 3 Histopathological Study
NCT05641688 ·Status: RECRUITING ·Phase: PHASE3
-
Evaluation of Age- and Alzheimer's Disease-Related Memory Disorder
NCT00029120 ·Status: COMPLETED
-
Multi-modal Neuroimaging in Alzheimer's Disease IMAP+
NCT01638949 ·Status: COMPLETED ·Phase: NA
-
Modelling in the Quantitative Analysis of Brain PET Scans in Patients With Alzheimer's Disease
NCT04718207 ·Status: COMPLETED
-
Risk of Developing Dementia and Associated Factors in Patients With Normal Brain FDG PET
NCT04804722 ·Status: COMPLETED
-
Brain Imaging in Elderly People and Individuals With Alzheimer's Disease
NCT00001917 ·Status: COMPLETED
-
Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
NCT02676843 ·Status: COMPLETED ·Phase: PHASE2
-
Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects.(Positron Emission Tomograph )
NCT02686216 ·Status: COMPLETED ·Phase: PHASE1
-
Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down Syndrome
NCT00965835 ·Status: UNKNOWN
-
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
NCT01680588 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects
NCT04141150 ·Status: UNKNOWN ·Phase: PHASE2
-
PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)
NCT02062099 ·Status: COMPLETED ·Phase: PHASE1
-
Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia
NCT00966017 ·Status: UNKNOWN